We're Making Changes to www.sigmaaldrich.com

Learn about the changes we are making to sigma-aldrich.com

Use the Order Center to build a Shopping Cart, view Saved Shopping Carts, Recent Orders and Quotes

MSDS

Search for MSDS (Material Safety Data Sheet) by Product Number

Oligo Ordering

Custom Products and Services, including DNA oligos (Primers and Probes), RNA, siRNA, Peptide Libraries and AQUA Peptides

Corporate

Sigma-Aldrich is a leading Life Science and High Technology Materials company focused on enabling science to improve the quality of life

Contact Us

Contact Customer Service

Request Literature

Request literature from Sigma-Aldrich

Newsletters

Subscribe to free eNews and other newsletters from Sigma-Aldrich

What disease, pathway or gene are you studying?

Save time searching for biological information and find products within the context of your research

Prestige Antibodies®

抗体の常識を超えた、ヒト抗体・発現データベースを備えたPrestige抗体は、常時新製品が追加されて1万製品。
ヒトターゲットタンパク質8400種類をカバーしています。

News and Information

Japan - March 2011 【東北地方太平洋沖地震】

このたびの東北地方太平洋沖を震源とする地震により被災された皆様には謹んでお見舞い申しあげます。

1日も早い復旧を社員一同心よりお祈り申しあげます。

Japan - 2011 【アンケート実施中】

2012年卓上カレンダー
★ニンテンドー3DSが当たるアンケート



【お知らせ】

その他のニュース、製品カタログ、セミナー、キャンペーンなどの最新情報は下記「READ MORE」をご参照下さい。

続きを読む
St. Louis, MO - January 9, 2012 Sigma-Aldrich Extends Laboratory Chemicals Contract with Honeywell

Sigma-Aldrich Corporation (NASDAQ: SIAL) announced today it has signed a five-year contract extension with Honeywell for the manufacture and supply of Riedel-de Haën® high purity solvents, Karl Fischer reagents and other laboratory chemicals produced at Honeywell's Seelze, Germany, manufacturing site. The contract extends an existing supply agreement, in place since 1999, through March 31, 2019.

Read More
St. Louis, MO - January 9, 2012 Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services

Sigma-Aldrich Corporation (NASDAQ:SIAL), a leading Life Science and High Technology company, announced it has signed an agreement to acquire BioReliance Holdings, Inc., a leading provider of global biopharmaceutical testing services, from Avista Capital Partners for $350 million in cash. The acquisition is subject to customary closing conditions, including regulatory clearance, and is expected to close in the first quarter of 2012.

Read More view all press releases